Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Capital Intensity

The Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 15, 2026 is 363.74 %. In the previous year, Capital Intensity Ratio was 331.08 % — a change of 9.87% (higher).

Capital Intensity

363.74 %

YoY

9.87%

Last updated:

Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp is 2025 363.74 % . Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp was 2024 331.08 % . It decreases by 9.87% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
336.49 CNY
Jan 1, 2019
352.51 CNY
Jan 1, 2020
369.97 CNY
Jan 1, 2021
327.84 CNY
Jan 1, 2022
339.87 CNY
Jan 1, 2023
340.40 CNY
Jan 1, 2024
331.08 CNY
Jan 1, 2025
363.74 CNY
The Vcanbio Cell & Gene Engineering Corp Capital Intensity history
YEARCapital IntensityYoY
363.74 %+9.87%
331.08 %-2.74%
340.40 %+0.15%
339.87 %+3.67%
327.84 %-11.39%
369.97 %+4.95%
352.51 %+4.76%
336.49 %+48.15%
227.13 %-36.64%
358.47 %-9.75%
397.20 %-21.63%
506.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp is 363.74 % in 2025.

Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp changed from 331.08 % to 363.74 %, representing a 9.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Vcanbio Cell & Gene Engineering Corp

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Vcanbio Cell & Gene Engineering Corp